CDDO-Im
Cat. No.：YN410069
| 产品名称: | CDDO-Im |
| CAS No.: | 443104-02-7 |
| Chemical Name: | 1-(2-cyano-3,12,28-trioxooleana-1,9(11)-dien-28-yl)-1H-imidazole |
| Synonyms: | RTA-403; TP-235; |
| 分子量: | 541.72 |
| 分子式: | C₃₄H₄₃N₃O₃ |
| SMILES: | CC(C)([C@]1([H])CC[C@@]([C@@]2(CC[C@]3(CCC(C)(C[C@@]3([H])[C@]24[H])C)C(N5C=CN=C5)=O)C)6C)C(C(C#N)=C[C@]1(C)C6=CC4=O)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | CDDO-Im (RTA-403) 是Nrf2和PPAR的活化剂，对 PPARα 和 PPARγ 的Ki分别为232 nM 和 344 nM。 |
| IC50和靶点: | [{name:"PPARα:232 nM (Ki)"},{name: "PPARγ:344 nM (Ki)'}, 'Nrf2'] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Liby, K., Hock, T., Yore, M.M., et al.The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signalingCancer Res.65(11),4789-4798(2005)
Meng, X., Waddington, J.C., Tailor, A., et al.CDDO-imidazolide targets multiple amino acid residues on the Nrf2 adaptor, Keap1J. Med. Chem.63(17),9965-9976(2020)
Place, A.E., Suh, N., Williams, C.R., et al.The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivoClin. Cancer Res.9(7),2798-2806(2003)
Chintharlapalli, S., Papineni, S., Konopleva, M., et al.2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor γ-dependent and -independent pathwaysMol. Pharmacol.68(1),119-128(2005)
Honda, T., Honda, Y., Favaloro, F.G., Jr., et al.A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide productionBioorg. Med. Chem. Lett.12(7),1027-1030(2002)
Hughes, D.T., Martel, P.M., Knlaw, W.B., et al.The synthetic triterpenoid CDDO-Im inhibits fatty acid synthase expression and has antiproliferative and proapoptotic effects in human liposarcoma cellsCancer Invest.26(2),118-127(2009)
